Nuclear receptors are transcription factors that can be activated by specific ligands. Recent progress has shown that retinoid X receptor (RXR) and its heterodimerization partners, including peroxisome proliferator-activated receptors, regulate many important genes involved in energy homeostasis and atherosclerosis, and should be promising therapeutic targets of metabolic syndrome. RXR heterodimers regulate a number of complex cellular processes, and genetic studies of RXR heterodimers have provided important clinical information in addition to knowledge gained from basic research. Genetic variants of RXR heterodimers were screened and investigated, and some variants were shown to have a considerable impact on metabolic disorders, including phenotypic components of familial combined hyperlipidemia. The combined efforts of basic and clinical science regarding nuclear receptors have achieved significant progress in unraveling the inextricably linked control system of energy expenditure, lipid and glucose homeostasis, inflammation, and atherosclerosis. This review summarizes the current understanding regarding RXR heterodimers based on their human genetic variants, which will provide new clues to uncover the background of multifactorial disease, such as metabolic syndrome or familial combined hyperlipidemia. 
ligands derived from cholesterol, fatty acids, and glucose 4, 5) to regulate target genes that mediate metabolic homeostasis. Recent studies indicated that not only PPARs but also other RXR heterodimers are attractive therapeutic targets for intervention in atherosclerosis 2, 3, 6) . Metabolic regulation of RXR heterodimers is complex, involving a great deal of cross-talk, and their clinical importance has been clarified through investigations of genetic variants. Familial combined hyperlipidemia (FCHL) is the most common form of hereditary hyperlipidemia, but its genetic background has not been fully elucidated. Increased in very-low density lipoprotein (VLDL) with or without that in low-density lipoprotein (LDL) is the main characteristic of patients with FCHL. The lipoprotein lipase (LPL) gene has been extensively studied due to its pivotal role in the hydrolysis of VLDL. Genetic variants of LPL have been reported to contribute to the lipid phenotype in FCHL 7, 8) , but LPL variants themselves were not linked to the FCHL phenotype. At present,
Introduction
Nuclear receptors contain a DNA-binding domain and a ligand-binding domain, and are activated by specific ligands to regulate target gene transcription. Clinically available lipid-lowering fibrates are activators of peroxisome proliferator-activated receptor alpha (PPAR ), and insulin-sensitizing thiazolidinediones (TZD) are activators of PPAR . These molecules are key regulators of metabolism and inflammation, and both play critical roles in the development of cardiovascular disease 1, 2) . Many nuclear receptors, especially retinoid X receptor (RXR) and its heterodimerization partners, play important roles in metabolic homeostasis 3) . RXR heterodimers bind to a variety of LPL is recognized as a modifier gene of the FCHL phenotype. "Intra-individual variability" of the lipoprotein phenotype is often included as a criterion in diagnosis 9) ; however, a recent prospective study of FCHL families suggests that this variability may even include normolipidemic periods in affected subjects 10) . This feature indicates that FCHL could be a "disease of regulation" rather than a genetic defect in certain peripheral components of lipid metabolism. As RXR heterodimers play pivotal roles in lipid metabolism, we screened all coding regions of PPAR , PPAR 2, PPAR , farnesoid X receptor (FXR), liver X receptor alpha (LXR ) and RXR genes in hyperlipidemic patients, including FCHL. We found that the RXR gene, located on the so-called "FCHL locus" on chromosome 1q21-q23, could contribute to the genetic background of FCHL 11) . This review summarizes the current understanding regarding RXR heterodimers, including PPARs, based on their human genetic variants ( Table 1) .
RXRs
RXRs are the major heterodimerization partners of the nuclear receptors mentioned below, and have three subtypes, RXR , RXR , and RXR 12) . No rexinoid (RXR-selective retinoid) with apparent subtype selectivity has been identified so far. RXR is predominantly expressed in the liver, kidney, epidermis, and intestine. RXR is ubiquitously expressed. RXR is expressed mostly in muscle, some parts of the brain, and very weakly in adipocytes with enhancement by TZD. RXR partners do not exhibit a marked preference for one of the three RXR subtypes in most cases. Drugs targeting heterodimerization partners of RXRs are already in clinical use for the treatment of cancer, endocrine disorders, dermatological diseases, and metabolic syndrome 3) . Despite numerous studies since their initial discovery, RXRs remain enigmatic nuclear receptors, and there is still no consensus regarding their role 13) . RXR heterodimer partners can be classified into functionally distinct "permissive" and "non-permissive" groups. PPARs, LXRs and FXR form permissive RXR heterodimers, which synergistically respond to both agonists of RXR and the partner receptor. Retinoic acid receptors (RARs), thyroid hormone receptor, and vitamin D receptor form non-permissive RXR heterodimers, which cannot be activated by an RXR agonist but only by the agonist of the partner receptor. Presumably, non-permissive partners inhibit RXR activation. RXRs can also form functional homodimers. Because few RXR-specific target genes have been identified, the importance of RXR homodimers in vivo has not been well established, but at least RXR homodimers can activate PPAR target genes in vivo 14) . These findings were established mainly by the RXR gene, and limited information is available about the RXR gene. Genetic or pharmacological modification of RXRs would result in changed RXR heterodimer function, also depending on its counterpartners, and furthermore, in changed RXR homodimer function, and this would be more complex with crosstalk than the modification of partner receptors.
It is known that retinoids, which activate both RARs and RXRs, induce hypertriglyceridemia through decreased clearance of VLDL by an LPL-dependent pathway 15, 16) ; however, the effects of rexinoids in lipid metabolism are less clear. Synthetic RXR ligands induced hypertriglyceridemia through decreased clearance of VLDL by LPL-dependent pathways 15, 16) , except in one study 17) . Recent studies suggest that different RXR agonists do not necessary display the same biological effects, and can target specific heterodimer partners 13) . In contrast to the high rates of embryonic lethality of RXR -and RXR -deficient mice, RXR -deficient mice are apparently normal, but have been reported to have reduced fasting plasma TG levels, increased skeletal muscle LPL activity, and less body weight gain due to low fat mass only when fed a highfat diet 18) .
Polymorphisms in RXR Gene and RXR Gene
Several polymorphisms have been reported in the RXR gene, but their associations with metabolic disorders have not been reported. Obesity and gallstones, both related to insulin resistance, are linked to an elevated risk of biliary cancer. Recently, Chang et al., a group in the National Institutes of Health of United States, reported that RXR c.51C T polymorphism is associated with a higher body mass index (BMI), higher risk of gallstones, and elevated risk of bile duct cancer 19) . Functional consequence of this SNP was not confirmed.
RXR Gene p.Gly14Ser
In humans, some RXR gene variants have been reported to be associated with free fatty acid levels and TG levels in familial type 2 diabetes, but none of the variants showed an altered coding sequence 20) . The human RXR gene is located in chromosome 1q21-q23, the so-called "FCHL locus" 21) , and linkage analysis and twin study indicated that the RXR gene was also linked with higher LDL-cholesterol and TG in Chinese and German families 22, 23) . We identified p.Gly14Ser in the RXR gene through mutation screening of RXR-heterodimers in hyperlipidemic patients, and the results indicated that RXR Ser14 variant was significantly more frequent in FCHL patients than in other forms of primary hyperlipidemia or the general population 11) . To establish the impact of the identified RXR variant on metabolic parameters and coronary atherosclerosis, anthropometric parameters and laboratory data from 175 patients with suspected coronary disease were evaluated. In their lipid profiles, RXR Ser14 carriers had higher TG, higher remnant-like lipoprotein particle cholesterol, lower high-density lipoprotein cholesterol (HDL-C), especially in the HDL2 subfraction, and lower apolipoprotein A levels. RXR Ser14 carriers showed a significantly higher coronary stenosis index than those with the wild-type allele 11) . Subjects with this variant also showed significantly lower LPL activities and protein levels in postheparin plasma; therefore, transfection assays were performed using the LPL promoter co-transfected with either wild-type RXR or the variant. Interestingly, RXR Gly14 significantly repressed ( 40%) LPL promoter activity, whereas RXR Ser14 showed even stronger repression ( 60%, p 0.001) 11) . These results indicated that RXR down-regulates human LPL gene expression, at least partially by a transcriptional mechanism, and that the newly identified RXR variant is a more potent repressor than the wild-type allele. These results suggest that variants of the RXR gene contribute to genetic dyslipidemia, including FCHL.
Other RXR Gene Polymorphisms
Among 14 variants identified in the RXR gene, 3 variants (SNP6, SNP11 and SNP13[rs10918169]) in strong linkage disequilibrium showed nominal association with type 2 diabetes mellitus in a case-control study 20) . They also found that these SNPs were associated with free fatty acids, TG and HOMA-IR.
Type 2 diabetes has been linked to chromosome 1q21-24 in multiple samples, including a Utah family sample. Hasstedt et al., a group from Utah University, reported that genotypes of 5 variant pairs, including RXR 3'-UTR SNP (rs10918169), accounted for 25.8% of the genetic variance in type 2 diabetes in these pedigrees 24) . Functional changes of these SNPs were not described.
PPARs
The roles of the PPAR family, PPAR , PPAR / , and PPAR , have been the subject of intensive investigation, because synthetic ligands of PPAR and PPAR are clinically available as therapeutic drugs. PPARs accept a relatively widerange of compounds as their agonists, which may be because of their large ligand-binding cavity 25) . PPARs have key roles as regulators of energy homeostasis and inflammation, and many synthetic ligands have been developed targeting the ment of treat metabolic disorders. PPARs are known to be expressed in several cancers, and even though the roles of PPAR and PPAR in carcinogenesis have not been confirmed, TZD is thought to be able to prevent the development of some cancers.
Recent studies have also revealed various unexpected roles of PPARs in cardiovascular homeostasis, as described below.
PPAR
PPAR -activating fibrates have been used in the treatment of dyslipidemia for a long time. Among fibrates, fenofibrate is known to be a relatively specific PPAR agonist, and bezafibrate is considered a panagonist of PPARs 26) . Bezafibrate showed cardiovascular event reduction in clinical trials, i.e., the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Bezafibrate Infarction Prevention (BIP) 27, 28) , and fenofibrate also showed coronary risk reduction in the Diabetes Atherosclerosis Intervention Study (DAIS) and Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial (no differences in the vprimary end point in the FIELD trial) 29, 30) . Lipid-lowering fibrates activate PPAR , which is expressed mainly in the liver and regulates many genes involved in the transport and -oxidation of free fatty acids 31) . PPAR enhances the "reverse cholesterol transport" pathway by up-regulation of not only apolipoprotein AI but also ABCA1 32) . PPAR is also expressed in the heart and muscle, where it plays a crucial role in controlling fatty acid oxidation. In the heart, PPAR seems to participate in mitochondrial biogenic response and hypertrophic transformation of cardiac myocytes. PPAR regulates the genes responsible for myocardial fatty acid oxidation and is downregulated during cardiac hypertrophy, concomitant with the switch from fatty acid to glucose utilization 33) . Animal studies have shown that PPAR activation prevents cardiac hypertrophy. A recent study demonstrated the induction of neo-angiogenesis by selective activation of PPAR and PPAR by a vascular endothelial growth factor-dependent mechanism 34) . PPAR expression is also found in vascular cells, including endothelial cells, vascular smooth muscle cells, and monocytes/macrophages. PPAR is also a key regulator of inflammatory response, which is a critical process in atherosclerosis 35) . PPAR activation can inhibit inflammatory response genes by repressing nuclear factor-B, a signal transducer and activator of transcription, and activator protein-1 signaling. PPAR activator inhibits interleukin (IL)-1-induced production of IL-6 and prostaglandin and the expression of cyclooxygenese-2 in vascular smooth muscle cells 35) . PPAR activation reduces vascular cell adhesion molecule-1 expression and increases NO expression and release in vascular cells, maintaining normal endothelial function. Thus, we expect that PPAR activation has potential cardio-protective effects in addition to the mere amelioration of dyslipidemia 36, 37) . PPAR 's important role in macrophages is well established. Unexpectedly, we found that PPAR induces NADPH oxidase activity in macrophages and generate endogenous PPAR ligands through LDL oxidation 38) . More recently, liver-specific PPAR was shown to control the acute-phase response 39) . Cross-talk between pleiotropic effects of statins and fibrates has also been examined 40) .
PPAR p.Leu162Val
A p.Leu162Val polymorphism of the PPAR gene has been widely reported in Europe and North American populations 41) . We screened the p.Leu162Val variant in the Japanese population, detecting no single individual with this variant 11) . Val162 was shown to be associated with increased LDL-C in the Framingham offspring study 42) , and with increased apolipoprotein B or TG in other studies 43, 44) , but the clinical features, especially with regard to obesity and diabetic risk are still controversial [44] [45] [46] A recent report from the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) showed that Val162 increased the risk of diabetes by 1.9-fold and was associated with increased plasma glucose and insulin lev- . Val162 is a gain-of-function variant, and the results of in vitro and animal studies suggested that this variant would have favorable effects on lipid and glucose metabolism; however, this variant actually seems to be associated with an unfavorable phenotype. Although Val162 is a gain-of-function variant with activating ligands, its basal transcription level is lower than that of the wild type. This might explain the differences between reports based on patient background. The results of the Framingham Heart Study indicated that Val162 is associated with greater TG and greater apolipoprotein C on low intake of polyunsaturated fatty acids (PUFA), a natural PPAR ligand; in contrast, Val162 was associated with lower apolipoprotein C when PUFA intake was high 48) . Val162 was also shown to be associated with less progression of diffuse coronary atherosclerosis 49) .
PPAR Intron7 G C
The intron7 G C variant (rs4253778) had also been investigated extensively. In subjects with type 2 diabetes, the G/G genotype was associated with a good response to fenofibrate treatment 50) . In cases of cardiac disease, intron7 C allele carriers showed greater coronary atherosclerosis progression 49) , premature coronary artery disease 51) and left ventricular hypertrophy 52) . The mechanism by which this variant affects PPAR function remains unclear.
Other PPAR Gene Variants
The p.Gln395Glu variant was identified in our Japanese population study 11) . This variant was associated with higher LDL-C in patients with suspected coronary artery disease, and in vitro assay indicated it to be a gain-of-function variant 11) . The p.Val227Ala variant has been reported in Asian populations 53, 54) . Ala227 was associated with lower total cholesterol (TC) and lower TG in Chinese women 53) , and with lower TC in a non-drinking group of Japanese men 54) . Ala227 was associated with a smaller waist circumference and non-alcoholic fatty liver disease in a Chinese population 55) . Ala227 showed reduced transactivation activity in an in vitro assay 56) . These data are consistent with higher TC or TG in individuals with PPAR gain-of-function variants; however, the mechanism of the discrepancy, that higher activity PPAR variants are associated with dyslipidemia, whereas PPAR activating fibrates ameliorate dyslipidemia, remains to be elucidated.
PPAR
Insulin-sensitizing thiazolidinediones (TZD) are ligands of PPAR . The PPAR 2 isoform is expressed solely in adipose tissues, and plays a critical role in adipogenesis. Some angiotensin-receptor-blockers, such as telmisartan, shows PPAR activation, and are expected to have an additional advantage 57) . There is no doubt of the clinical usefulness of TZD in the amelioration of diabetes mellitus, but there is controversy regarding its efficacy in cardiovascular disease. Meta-analysis data have suggested possible adverse cardiovascular outcomes with rosiglitazone, in contrast with pioglitazone which shows protective effects in the secondary prevention of cardiovascular disease [58] [59] [60] [61] . We must be awase that these meta-analyses were not conducted to compare rosiglitazone and pioglitazone, and the clinical settings may not have been comparable between these two drugs. Deeg et al. reported that at least their effects on lipoproteins were significantly different between type 2 diabetes and dyslipidemic patients in a head-to-head randomized clinical study 62) . Pioglitazone showed more favorable changes in VLDL, LDL and HDL than rosiglitazone.
Rosiglitazone is a specific ligand solely for PPAR , whereas pioglitazone partially activates PPAR . Pioglitazone treatment causes a reduction in plasma TG concentrations, while rosiglitazone had the opposite effect; these observations may be associated with the partial agonistic action of pioglitazone on PPAR receptors. Clinical advantages may be influenced by the pharmacological differences between these drugs 26, 63) . It is interesting that balanced agonists of PPARs may be better than highly specific ligands for one isoform in some clinical trials.
PPAR is also expressed in the collecting ducts of the kidney, and TZD-induced edema can be accounted for by renal salt absorption 64) . There is a report that the use of rosiglitazone was associated with an increased risk of congestive heart failure and mortality compared with pioglitazone in a large cohort of elderly individuals with diabetes 65) . PPAR has been shown to be a key regulator in differentiation toward adipocytes and to osteoblasts and osteoclasts 66, 67) . PPAR activation enhances adipocyte differentiation and inhibits osteoblast differentiation from mesenchymal stem cells, and osteoclast maturation from precursors. It has recently been suggested that TZD-induced skeletal fragility 68) may be attributable to these regulation systems.
PPAR 2 p.Pro12Ala
The common p.Pro12Ala in the PPAR 2 gene is the most extensively investigated polymorphism in RXR heterodimers; however, the clinical impact of this polymorphism is complex. The Ala12 variant shows moderately reduced transcriptional activity of PPAR 2 69) , and is shown to be associated with lower BMI, increased insulin sensitivity, and being consequently protective against diabetes 70) . Indeed, it has been reported that the Ala12 allele was associated with a reduced incidence of cardiovascular disease [71] [72] [73] ; however, in some large-scale studies, the Ala12 allele was also shown to be associated with unfavorable phenotypes, such as increased waist circumference or increased BMI [74] [75] [76] [77] [78] [79] [80] . The potential mechanism of how this polymorphism would exert its effect is its influence on adipose tissue development and adiposederived cytokines. Some investigators have reported that the Ala12 allele was associated with decreased plasma adiponectin levels in the Japanese population 81, 82) . These inconsistencies were suggested to be because the protective effect of the Ala12 allele may be lost once diabetes has developed 70) .
A recent meta-analysis of ~32,000 non-diabetic subjects in 57 studies showed no clear association between diabetic traits and this polymorphism, but in selected subgroups, such as Caucasians and obese subjects, associations were observed between the Ala12 allele and both greater BMI and increased insulin sensitivity 83) . Using stable isotope techniques, a mixed meal study in vivo showed that Ala12 carriers had lower plasma fatty acid levels, higher adipose and muscle blood flow, and greater insulin sensitivity than Pro12 homozygotes 84) . BMI and insulin sensitivity may counteract each other in subjects with the Ala12 allele.
Very recently, a study on Pro12Ala knockin mice was reported 85) . In this animal model, Ala/Ala mice on a chow diet are leaner and have improved insulin sensitivity and plasma lipid profiles, but high-fat feeding eliminated these beneficial effects, with changes in cofactor interaction and adiponectin signaling. These data suggest the key role of gene-environment interactions, and may explain some inconsistencies in the human phenotype.
As TZD drugs are known to potentially induce edema, PPAR is expressed in the kidney. This can affect the function and prognosis of diabetic nephropathy, blood pressure, and also the prognosis of cardiovascular disease through chronic kidney disease. Recent studies showed that the Ala12 allele is associated with enhanced decline in the glomerular filtration rate and predicts end-stage renal disease, and is also associated with cardiovascular disease and mortality in diabetic patients with nephropathy [86] [87] [88] ; however, the opposite effect of this genotype on cardiovascular disease has been reported in subjects without chronic kidney disease [71] [72] [73] . We speculate that the presence of nephropathic disease may affect the results of these controversial reports on this polymorphism.
With regard to the response to TZD treatment, subjects with the Ala12 allele showed a better response to therapy than those with Pro12 homozygotes in one study 89) , and no difference was observed between the two genotypes in another 90) ; however, the Ala12 allele was the most important risk factor for TZD-induced edema 91) . As PPAR plays an important role in osteocyte differentiation 66, 67) , it is possible to speculate on its association with bone metabolism. Rhee et al. reported that the Ala12 allele was associated with the serum osteoprotegerin level, a key inhibitor of osteoclastogenesis, in a Korean population 92) .
Other PPAR Gene Variants
A gain-of-function p.Pro115Gln variant is associated with obesity and insulin resistance 93, 94) . A silent c.161C T (1431C T: rs3856806) polymorphism in exon 6 of the PPAR gene was investigated in several studies. Doney et al. reported that the T allele of this polymorphism is associated with increased body weight, but this allele is in strong linkage disequilibrium with the Pro12Ala variant, so they suggested that the opposing interaction between c.161C T and Pro12Ala variant might be one reason for the inconsistent effect of these genotypes 95) . They reported that the Ala12 allele was protective against diabetes in their study; however, this protective effect, attributable to the Ala12 variant, was absent when the Ala12 variant was presentwith the T allele of c161C T 96) . However, no such opposite interaction or additive effects between c.161C T and p.Pro12Ala was confirmed in another study, and the T allele was associated with a decreased risk of diabetes 97) . Reduced coronary artery disease risk and lower TG were associated with the T allele 98, 99) , but a cohort study also indicated an association with higher coronary risk 96) . Another study suggested that, in obese subjects, the T allele was shown to be associated with higher plasma leptin levels 100) . A series of rare loss-of-function mutations (p.Cys114Arg, p.Cys131Tyr, p.Cys162Trp, p.Cys190Ser, p.Val290Met, FS315X, p.Arg357X, p.Phe388Leu, p.Arg425Cys, p.Pro467Leu) were reported in partial lipodystrophy patients, and most were described as dominant-negative type [101] [102] [103] [104] [105] [106] [107] [108] . These patients showed insulin resistance and dyslipidemia. Lipodystrophic patients with p.Pro467Leu mutation showed high systemic nonesterified fatty acid (NEFA) because of the excessive and uncontrolled generation of NEFA directly from TG-rich lipoproteins 109) .
PPAR
PPAR is ubiquitously expressed as a key regula-tor of fatty acid oxidation and energy uncoupling. This less tissue-specific PPAR has not been the focus of as much attention as PPAR and PPAR as a therapeutic target; however, recent progress has shown that PPAR critically regulates fatty acid oxidation and energy dissipation in skeletal muscle and adipose tissue, and should be a promising target in the treatment of metabolic syndrome 110) . PPAR modulates insulin sensitivity through the regulation of adipose tissue-and hepatic-resident macrophage regulation 111, 112) . Recently, PPAR agonists have been reported to be "exercise mimetics" and increase exercise endurance without exercise in mice, suggesting a unique therapeutic approach for life-style-related disease 113) . PPAR also regulates multiple pro-inflammatory pathways to suppress atherosclerosis 114) , and plays some roles in angiogenesis with endothelial progenitor cells 115) . Recent investigations have revealed that PPAR is intimately involved in metabolic regulation and atherosclerosis.
PPAR c.-87T C
No mutations resulting in amino acid substitution have yet been identified in the PPAR gene, which was also the same in our study 11) . Several silent nucleotide substitution and non-coding region polymorphisms in the PPAR gene have been investigated for their clinical phenotype, but there have been few detailed studies regarding the functional consequences of these variants. Skogsberg et al. reported that in 4 polymorphisms, only the rare C allele of c.-87T C in exon4 (also named 294T C) showed a significant association with increased LDL-C levels in healthy men 116) . The C allele was associated with higher transcriptional activity 116) . This C allele of c.-87T C polymorphism was also shown to be associated with unfavorable phenotypes, such as low HDL-C in women 117) , and increased fasting plasma glucose 118, 119) . On the other hand, from the analysis of 15 PPAR polymorphisms among subjects without type 2 diabetes or hereditary dyslipidemia in French-Canadians, only the C allele of c.-87T C showed an association with favorable phenotypes, such as a lower risk of metabolic syndrome 120) , and lower BMI, the latter of which was reported in another Caucasian group 121) . From the standpoint of individual differences in responsiveness to 20 weeks of endurance exercise training, the C allele of -87T C was associated not only with smaller training-induced increase in maximal oxygen consumption and lower training response in maximal power output, but also with a greater increase in plasma HDL-C with physical training (HERITAGE Family Study) 122) .
Other PPAR Gene Polymorphisms
Several haplotype analyses with SNPs showed significant metabolic phenotypes even though functional consequences were not determined. Shin et al. reported that a major haplotype (ht1) with 5 SNPs was associated with lower BMI in Korean subjects 118) . Vanttinen et al. reported that most common haplogenotype (named hgt1) with 3 SNPs was associated with lower skeletal muscle glucose uptake detected by FDG-PET scanning, higher systolic blood pressure, higher TC, and higher LDL-C in a Finnish population 123) . With regard to lifestyle intervention, Thamer et al. reported that carriers of minor allele 3 SNPs showed reduced responses in adipose tissue mass, hepatic lipids evaluated by MRI, and a reduced increase in muscle volume of the leg after 9-month exercise and a dietary lifestyle-intervention program 124) . As the PPAR gene is expressed at high levels in skeletal muscle and adipose tissue, genetic studies suggested a significant genetic contribution of PPAR to metabolic homeostasis, presumably modified by its interactions with lifestyle.
LXRs
LXRs and FXR have been described as cooperation regulators in cholesterol absorption, secretion, and synthesis. LXR is an oxysterol sensor, and its subfamily consists of LXR and LXR . LXR is expressed mainly in the liver, small intestine, macrophages and adipose tissue, and is the target gene of PPAR , whereas LXR is expressed ubiquitously. In response to increased cellular oxysterols, LXRs activate genes involved in the "reverse cholesterol transport" system, cholesterol efflux from peripheral tissues or macrophages, transport in serum, uptake into liver, cholesterol catabolism into bile acids, biliary secretion of cholesterol, and inhibition of cholesterol absorption. LXRs also activate SREBP-1c, the master regulator of fatty acid synthesis 125, 126) . Studies in LXR -and LXR -deficient mice suggest a more prominent role of LXR than LXR in lipid metabolism 127, 128) . LXR agonists not only decrease cholesterol absorption and increase HDL-C with NPC1L1 129) , but also induce hypertriglyceridemia, mostly via SREBP-1c activation, and this may potentially hamper drug development. Moreover, both LXR isoforms are expressed in skeletal muscle and are associated with lipid accumulation 130) . Mitro et al. reported in Nature that LXR is also a glucose sensor, and can integrate hepatic glucose metabolism and fatty acid synthesis 4) , but a contradictory paper by Denechaud et al. has also been published 131) .
LXRs also play important roles in immune and inflammatory responses 132) . We demonstrated their roles in innate immunity that LXR activation regulates TLR4 and potentiates immune responses in human macrophages 133) .
LXR Gene Polymorphisms
Recently, LXR gene polymorphisms were reported to be associated with metabolic syndrome in two large populations 134) . They genotyped 3 SNPs, and found that only the A allele of c.-6G A polymorphism was associated with a 30% reduction in the risk of metabolic syndrome and an increase in plasma HDL-C 134) . Human primary macrophages were analyzed for their mRNA levels of LXR and ABCA1 as a target of LXR , but no significant differences were confirmed. The c.-6G A polymorphism is included in the Kozak sequence, which may affect translational efficiency.
LXR c.-115G A, c.-840C A and c.-1830 T C genotypes were analyzed in a French-Canadian population, and -155A, -180A and -1830C alleles were associated with higher plasma TC. High cholesterol intake was associated with higher TC in -155A carriers, suggesting that cholesterol intake interacts with LXR variants to modulate lipid profiles 135) . The LXR rs2279238 SNP was shown to be associated with female obesity 136) . The functional consequences of these SNPs were not determined.
Moreover, LXR gene polymorphisms were shown to be associated with human life span in a population-based prospective follow-up study 137) . Mooijaart et al. tagged four common haplotypes with 4 genotyp SNPs, and found that "haplotype 2" was associated with reduced mortality during 7-year follow-up, predominantly caused by reduced mortality from infectious disease 137) . Haplotype 2 was also associated with higher levels of plasma apolipoprotein E, a target gene of LXR , and higher levels of TG.
A limited number of clinical studies indicated associations between LXR and metabolic disorders. Eleven SNPs in LXR were genotyped in obese and non-obese women, and 2 SNPs (LB44732G/A and rs2695121) were associated with obesity phenotypes 136) . The functional consequences of these SNPs were not determined.
FXR
FXR is a bile acid sensor, which controls cholesterol and bile acid homeostasis through the enterohepatic circulation in cooperation with LXRs, and also has important roles in glucose homeostasis [138] [139] [140] [141] . Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c 142) . Chenodeoxycholic acid (CDCA) is the most potent natural agonist of human FXR and was evaluated to treat hypertriglyceridemia, but the TG-lowering effect was transient and showed side effects, such as liver toxicity or diarrhea 141) . Watanabe et al. reported that bile acids induce energy expenditure, preventing obesity and insulin resistance 143) . Recently, bile acid-binding resins have attracted attention as a new means of preventing and treating obesity, insulin resistance, and diabetes 144) . Bile acids are now appreciated as "complex metabolic integrators" and not just as lipid solubilizers or simple regulators of bile acid homeostasis, and bile acid signaling pathways have become attractive therapeutic targets of metabolic disorders, including obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis and non-alcoholic steatohepatitis 145) , even though FXR may not be the main target of treatment.
FXR Gene Polymorphisms
There have been only a few reports regarding FXR gene polymorphisms and metabolic disorders. We identified a common c.-1G T polymorphism of one nucleotide preceding the start codon in a Japanese population 11) , and also in other ethnic groups 146) . The T allele of the c.-1G T polymorphism showed reduced transactivation, and was associated with decreased hepatic target gene expression 146) . Further investigation regarding this polymorphism is on going.
Conclusions
The combined efforts of basic and clinical science regarding nuclear receptors have achieved significant progress in unraveling the inextricably linked control system of energy expenditure, lipid and glucose homeostasis, inflammation, and atherosclerosis. It is quite interesting to see clinical studies of genetic variants of RXR heterodimers sometimes revealing results somehow contrary to those expected from the pharmacological effects of their activators. Understanding the cross-talk mechanisms with RXR heterodimers will provide new clues to uncover the background of multifactorial disease, such as metabolic syndrome or FCHL. There are still numerous unanswered questions, but the discovery of new pathways will lead to the establishment of new strategies for the prevention and treatment of dyslipidemia, obesity, diabetes, and cardiovascular disease. 
